Leadership in health care private equity since 1986

The Latest News

February 19, 2019

ElectroCore and HealthyWomen Announce Partnership>

Patient Program to Increase Awareness of Non-Drug Migraine Therapies

January 08, 2019

ElectroCore Announces Two New Studies and a Publication>

Findings Support the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults

January 08, 2019

ElectroCore Announces Two New Studies and a Publication>

Increasing Support of the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults

January 02, 2019

Exagen Enters Second-Year Agreement with GSK>

Collaboration to drive greater awareness about challenges facing lupus diagnosis and management 

January 02, 2019

GammaCore™ Now Available Through U.S. Federal Government’s Federal Supply Schedule (FSS)>

Five-year contract makes gammaCore™ available to the over 21 million patients managed within the Department of Veteran’s Affairs, Department of DefenseBureau of PrisonsIndian Health Servicesand Public Health Services

November 28, 2018

ElectroCore Receives FDA Clearance for gammaCore™ (nVNS) for Adjunctive Use for the Preventive Treatment of Cluster Headache in Adults>

First and only product FDA cleared for the prevention of cluster headache. There are currently no FDA-approved pharmacologic treatments for the prevention of cluster headache.

November 27, 2018

ElectroCore Expands Manufacturing Capabilities for gammaCore™>

New design and development facility to support increasing patient demand.

November 13, 2018

ElectroCore, Inc. Announces Third Quarter Financial Results>

Fnancial results for the three months and nine months ended September 30, 2018.

November 08, 2018

Alphatec Reports Third Quarter 2018 Financial and Corporate Highlights>

Results for the third quarter ended September 30, 2018 and corporate highlights.

November 07, 2018

TriSalus Life Sciences’ Pressure-Enabled Drug Delivery (PEDD) Significantly Increased Therapeutic Effect of Anti-CEA CAR-T in Pancreatic Cancer Patients with Liver Metastases>

  • PEDD overpowers intratumoral high pressure, significantly increasing CAR-T into solid tumors
  • Median overall survival (OS) 8.3 months and mean OS 9.8 months vs. 3 to 6 months standard of care
  • Two of four stage IV patients who failed systemic chemotherapy showed metabolic complete response (CR); no visible liver metastases on PET
November 05, 2018

SupplyPro Named to Silicon Review's 50 Best Workplaces 2018>

Developing investory management solutions to improve manufacturing profitability and streamline operations.

November 01, 2018

SupplyPro® Unveils New SupplySystem Intelligent Software™ for Inventory Management>

SupplySystem IS Leverages Advanced Technologies to Deliver a Competitive Advantage

October 26, 2018

TriSalus Life Sciences Names Chief Business Officer>

Leadership appointment supports strategic shift to build oncology drug delivery company

October 23, 2018

NICE Publishes Advice on gammaCore for the Treatment of Cluster Headache in the UK>

Report contributors agreed gammaCore was highly innovative, may be more effective than standard of care alone, and has the potential to save money through the NHS by reducing the cost of treating cluster headache.

October 12, 2018

Exagen Announces Launch of Novel Biomarker PC4d Associated with Thrombosis in Lupus>

Makers of the rapidly growing AVISE CTD test expands portfolio of patented CB-CAPs blood tests

October 04, 2018

OrthoSensor Announces Milestone of 50,000 VERASENSE™ Sensors Distributed Globally>

VERASENSE is transforming primary and revision total knee replacement for surgeons and patients across the globe.

October 02, 2018

Exagen Featured in Eight Scientific Presentations at The 2018 ACR/ARHP Annual Meeting in Chicago>

Leading immunology laboratory continues strides with first ever economic impact data for AVISE Lupus

September 26, 2018

Alphatec Advances Clinical Distinction With OsseoScrew® Clearance>

Alphatec's OsseoScrew® System received 510(k) clearance from the U.S. Food & Drug Administration (FDA), making it available for clinical use for the first time in the United States. 

September 12, 2018

Surefire Medical to Change Name to TriSalus Life Science>

New company name better represents contribution to patient care